Evidence map›Paper›PMID 30804745›Full record

ArticleFrontiers in neuroscience2019

Oxidative Stress Related to Iron Metabolism in Relapsing Remitting Multiple Sclerosis Patients With Low Disability.

Mariacristina Siotto, Maria Maddalena Filippi, Ilaria Simonelli, Doriana Landi, Anna Ghazaryan, Stefano Vollaro, Mariacarla Ventriglia, Patrizio Pasqualetti, Mauro Ciro Antonio Rongioletti, Rosanna Squitti and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 2 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Oxidative Stress in Brain Function.Antioxidants (Basel, Switzerland) · 2025
    Review
  9. Article
  10. Review
  11. Oxidative Stress Markers in Multiple Sclerosis.International journal of molecular sciences · 2024
    Review
  12. Review
  13. Article
  14. Amelioration of nephrotoxicity by targeting ferroptosis: role of NCOA4, IREB2, and SLC7a11 signaling.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2024
    Article
  15. Article
  16. Review
  17. Risk Factors from Pregnancy to Adulthood in Multiple Sclerosis Outcome.International journal of molecular sciences · 2022
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Mariacristina SiottoIRCCS Fondazione Don Carlo Gnocchi, Milan, Italy.
Maria Maddalena FilippiFatebenefratelli Foundation for Health Research and Education, AFaR Division, Rome, Italy.
Ilaria SimonelliService of Medical Statistics and Information Technology, Fatebenefratelli Foundation for Health Research and Education, AFaR Division, Rome, Italy.
Doriana LandiMultiple Sclerosis Clinical and Research Unit, Department of Systems Medicine, Tor Vergata University, Rome, Italy.
Anna GhazaryanFatebenefratelli Foundation for Health Research and Education, AFaR Division, Rome, Italy.
Stefano VollaroNeurology Unit, Campus Bio-Medico University of Rome, Rome, Italy.
Mariacarla VentrigliaFatebenefratelli Foundation for Health Research and Education, AFaR Division, Rome, Italy.
Patrizio PasqualettiService of Medical Statistics and Information Technology, Fatebenefratelli Foundation for Health Research and Education, AFaR Division, Rome, Italy.
Mauro Ciro Antonio RongiolettiDepartment of Laboratory Medicine, Research and Development Division, "San Giovanni Calibita", Fatebenefratelli Hospital, Rome, Italy.
Rosanna SquittiIRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
Fabrizio VernieriNeurology Unit, Campus Bio-Medico University of Rome, Rome, Italy.
Fatebenefratelli Hospital · ITUniversità Campus Bio-Medico · ITDon Carlo Gnocchi Foundation · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oxidative status may play a role in chronic inflammation and neurodegeneration which are considered critical etiopathogenetic factors in Multiple Sclerosis (MS), both in the early phase of the disease and in the progressive one. The aim of this study is to explore oxidative status related to iron metabolism in peripheral blood of stable Relapsing-Remitting MS with low disability. We studied 60 Relapsing-Remitting MS patients (age 37.2 ± 9.06, EDSS median 1.0), and 40 healthy controls (age 40.3 ± 10.86). We measured total hydroperoxides (dROMs test) and Total Antioxidant Status (TAS), along with the iron metabolism biomarkers: Iron (Fe), ferritin (Ferr), transferrin (Tf), transferrin saturation (Tfsat), and ceruloplasmin (Cp) panel biomarkers [concentration (iCp) and enzymatic activity (eCp), copper (Cu), ceruloplasmin specific activity (eCp:iCp), copper to ceruloplasmin ratio (Cu:Cp), non-ceruloplasmin copper (nCp-Cu)]. We computed also the Cp:Tf ratio as an index of oxidative stress related to iron metabolism. We found lower TAS levels in MS patients than in healthy controls (CTRL) and normal reference level and higher dROMs and Cp:Tf ratio in MS than in healthy controls. Cp and Cu were higher in MS while biomarkers of iron metabolism were not different between patients and controls. Both in controls and MS, dROMs correlated with iCp (CTRL

Indexed as

ceruloplasminceruloplasmin:transferrin ratiohydroperoxidesiron metabolismmultiple sclerosisoxidative stresstotal antioxidant status

Identifiers

PMID30804745
PMCPMC6378854
OpenAlexW2913897424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.